Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million

Poxel SA, a clinical-stage biopharmaceutical company, has agreed to sell its experimental kidney‑disease drug PXL770 to Scynexis Inc. in a deal worth up to $196 million. The transaction includes an $8 million upfront payment, with as much as $188 million tied to development and commercial milestones.

PXL770 (set to be renamed SCY‑770) is a first‑in‑class activator of AMPK, a mechanism aimed at slowing cyst growth in autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end‑stage renal disease. The drug has orphan‑drug designation in the U.S. and patent protection extending through at least 2041.

A Phase 2 proof‑of‑concept trial is expected to begin in the fourth quarter of 2026, with an initial efficacy review planned for the second half of 2027.

The sale allows Poxel to shift focus to its remaining pipeline programs, including TWYMEEG and PXL065, while Scynexis expands its portfolio of therapies targeting severe and rare diseases.